Seth Wander, MD, PhD, discusses approved and upcoming targeted therapies for patients with ESR1-mutated breast cancer.

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

The regulatory filing for the drug did not specify that use should be limited to the ESR1-positive population, so the FDA has approved a narrower label than originally sought when Stemline filed ...

This has the potential to change practice, but we need to wait for the full trial results and subsequent FDA approval,” she .

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

ESR1 mutations are a common cause of acquired ... The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ...

“These data from VERITAC-2 support the potential of vepdegestrant to give patients whose tumors harbor ESR1 mutations additional time without disease progression, compared to fulvestrant.

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.